Cognitive Enhancement Therapy for Early-Stage Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Cognition, Enhancement, Randomized
Eligibility Criteria
Inclusion Criteria: DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder at the time of initial assessment Pre-treatment illness duration an average of 5 years, not to exceed 8 years Stable positive symptoms (e.g., if present do not grossly interfere with behavior such as command hallucinations or delusions) Currently maintained and compliant with prescribed antipsychotic medication Socially and cognitively disabled, e.g., meet criteria on a Cognitive Style Scale (score greater than or equal to 7), and Social Cognition Disability Scale (score greater than or equal to 12). Exclusion Criteria: Alcohol/drug abuse or dependence that has significantly interfered with adjustment in the past two months (e.g., patients currently undergoing D and A treatment must successfully complete their recovery program prior to referral) Organic brain syndrome, including HIV illness (due to its effect on CNS function) IQ below 80 or language skills below the sixth grade level Medical contraindications that preclude an appropriate antipsychotic medication Persistent suicidality
Sites / Locations
- University of Pittsburgh
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Participants will receive cognitive enhancement therapy
Participants will receive enriched supportive therapy